Clinical Trial Update: Effect of Darbepoetin in Contrast-induced Nephropathy [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial of darbepoetin for preventing contrast-induced nephropathy in acute kidney injury has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury

Drugs mentioned

• Darbepoetin (darbepoetin alfa)

Snippet

Sponsor: Seoul National University Bundang Hospital | Conditions: Acute Kidney Injury | Phase 2, Phase 3 | Status: TERMINATED